^
    Back
    Association details:
    Biomarker:BCL2 overexpression
    Cancer:Hodgkin Lymphoma
    Regimen: (bleomycin + cyclophosphamide + doxorubicin hydrochloride + etoposide IV + Matulane (procarbazine hydrochloride) + prednisone + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    EHA 2022
    Title:

    ASSOCIATION OF BCL-2 EXPRESSING TUMOR CELLS WITH RESPONSE TO FRONTLINE CHEMOTHERAPY IN NODULAR SCLEROSIS HODGKIN LYMPHOMA

    Published date:
    05/12/2022
    Excerpt:
    Depending on the response to the 1st line therapy according to the BEACOPP-14 regimen, the subjects were divided into 2 groups....The optimal threshold value for the proportion of BCL-2+ tumor cells was 46%. Based on the established threshold, all subjects were divided into two categories: with high (≥46%) and low (<46%) BCL-2 expression....A high relative content of BCL-2+ tumor cells (>46%) is associated with treatment failures in patients with NSCHL.